Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a report issued on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $205.00 target price on the specialty pharmaceutical company's stock.

Other equities analysts have also recently issued reports about the company. UBS Group lowered their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a neutral rating on the stock in a report on Tuesday, July 2nd. Wells Fargo & Company dropped their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an equal weight rating on the stock in a research report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an overweight rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday. HC Wainwright reissued a buy rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an overweight rating in a report on Monday, August 19th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus target price of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $0.64 during mid-day trading on Tuesday, hitting $107.10. 480,122 shares of the company traded hands, compared to its average volume of 690,255. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $137.57. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The stock has a 50-day moving average price of $109.75 and a two-hundred day moving average price of $111.97. The stock has a market cap of $6.61 billion, a price-to-earnings ratio of 21.91, a P/E/G ratio of 1.34 and a beta of 0.57.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Capital World Investors bought a new position in shares of Jazz Pharmaceuticals during the first quarter worth $171,943,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $106,936,000. Vestal Point Capital LP purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $89,175,000. Rubric Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $65,812,000. Finally, Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after purchasing an additional 527,187 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.